Karen Thibaudeau

492 total citations
24 papers, 392 citations indexed

About

Karen Thibaudeau is a scholar working on Surgery, Hematology and Cancer Research. According to data from OpenAlex, Karen Thibaudeau has authored 24 papers receiving a total of 392 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Surgery, 8 papers in Hematology and 4 papers in Cancer Research. Recurrent topics in Karen Thibaudeau's work include Xenotransplantation and immune response (9 papers), Protease and Inhibitor Mechanisms (4 papers) and Blood Coagulation and Thrombosis Mechanisms (3 papers). Karen Thibaudeau is often cited by papers focused on Xenotransplantation and immune response (9 papers), Protease and Inhibitor Mechanisms (4 papers) and Blood Coagulation and Thrombosis Mechanisms (3 papers). Karen Thibaudeau collaborates with scholars based in United States, France and Canada. Karen Thibaudeau's co-authors include Dominique Bridon, Martin Robitaille, Pieter van Wyk, Omar Quraishi, Roger Léger, Nathalie Bousquet-Gagnon, Dominique Blanchard, Jean‐Paul Soulillou, Véronique Paradis and Jean‐Paul Castaigne and has published in prestigious journals such as Journal of Biological Chemistry, Blood and Endocrinology.

In The Last Decade

Karen Thibaudeau

22 papers receiving 372 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Karen Thibaudeau United States 12 128 125 57 54 50 24 392
M Hoffman United States 10 139 1.1× 300 2.4× 88 1.5× 180 3.3× 34 0.7× 20 619
C Vogt Germany 12 92 0.7× 143 1.1× 29 0.5× 19 0.4× 49 1.0× 25 436
Hannes Kalscheuer Germany 12 85 0.7× 69 0.6× 49 0.9× 97 1.8× 22 0.4× 17 409
Hans-Peter Harthus Germany 11 262 2.0× 216 1.7× 353 6.2× 53 1.0× 148 3.0× 19 796
Sarah E. Ackerman United States 8 50 0.4× 151 1.2× 10 0.2× 74 1.4× 59 1.2× 9 558
Weiyi Gao China 10 31 0.2× 367 2.9× 23 0.4× 42 0.8× 25 0.5× 16 589
Thomas Egebjerg Denmark 7 17 0.1× 87 0.7× 26 0.5× 17 0.3× 35 0.7× 12 447
Charles J. Kroger United States 13 99 0.8× 73 0.6× 90 1.6× 141 2.6× 11 0.2× 17 428
Jean Brown United Kingdom 6 50 0.4× 201 1.6× 23 0.4× 31 0.6× 76 1.5× 8 531
Dag Malm Norway 13 48 0.4× 213 1.7× 27 0.5× 43 0.8× 14 0.3× 28 766

Countries citing papers authored by Karen Thibaudeau

Since Specialization
Citations

This map shows the geographic impact of Karen Thibaudeau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karen Thibaudeau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karen Thibaudeau more than expected).

Fields of papers citing papers by Karen Thibaudeau

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karen Thibaudeau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karen Thibaudeau. The network helps show where Karen Thibaudeau may publish in the future.

Co-authorship network of co-authors of Karen Thibaudeau

This figure shows the co-authorship network connecting the top 25 collaborators of Karen Thibaudeau. A scholar is included among the top collaborators of Karen Thibaudeau based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karen Thibaudeau. Karen Thibaudeau is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shapiro, Amy D., Heather L. McDaniel, Robert W. Decker, et al.. (2025). Safety and Efficacy of Long‐Term Treatment of Type 1 Plasminogen Deficient Patients With Intravenous Plasminogen Replacement Therapy. Haemophilia. 31(3). 477–484. 1 indexed citations
2.
3.
Decker, Robert W., et al.. (2024). Nonhealing Surgical Wounds in a Patient with Plasminogen Deficiency Type 1 Successfully Treated with Intravenous Plasminogen: A Case Report. Advances in Skin & Wound Care. 37(7). 387–391. 1 indexed citations
4.
Shapiro, Amy D., Charles Nakar, Joseph M. Parker, et al.. (2023). Plasminogen, human‐tvmh for the treatment of children and adults with plasminogen deficiency type 1. Haemophilia. 29(6). 1556–1564. 7 indexed citations
5.
Dupuis, Jocelyn, Pierre Laurin, Jean‐Claude Tardif, et al.. (2022). Fourteen-Day Evolution of COVID-19 Symptoms during the Third Wave in Nonvaccinated Subjects and Effects of Hesperidin Therapy: A Randomized, Double-Blinded, Placebo-Controlled Study. Evidence-based Complementary and Alternative Medicine. 2022. 1–10. 12 indexed citations
6.
Thibaudeau, Karen, et al.. (2020). Painting the Clinical Picture of Congenital Plasminogen Deficiency (C-PLGD) through a Comprehensive Case Study Review. Blood. 136(Supplement 1). 21–22. 2 indexed citations
7.
Baraboi, Elena‐Dana, Chantal Michel, Pauline Smith, et al.. (2010). Effects of albumin‐conjugated PYY on food intake: the respective roles of the circumventricular organs and vagus nerve. European Journal of Neuroscience. 32(5). 826–839. 36 indexed citations
8.
Stoddart, Cheryl A., Sofiya A. Galkina, Karen Thibaudeau, et al.. (2008). Albumin-conjugated C34 Peptide HIV-1 Fusion Inhibitor. Journal of Biological Chemistry. 283(49). 34045–34052. 53 indexed citations
9.
10.
Léger, Roger, Karen Thibaudeau, Martin Robitaille, et al.. (2004). Identification of CJC-1131-albumin bioconjugate as a stable and bioactive GLP-1(7–36) analog. Bioorganic & Medicinal Chemistry Letters. 14(17). 4395–4398. 52 indexed citations
11.
Holmes, Darren L., et al.. (2000). Site Specific 1:1 Opioid:Albumin Conjugate with in Vitro Activity and Long in Vivo Duration. Bioconjugate Chemistry. 11(4). 439–444. 17 indexed citations
12.
Richard, Christelle, Karen Thibaudeau, Béatrice Charreau, et al.. (1998). Characterization of a murine monoclonal antibodv specific for swine β1 integrin. Xenotransplantation. 5(1). 75–83. 9 indexed citations
13.
Wolf, Philippe, et al.. (1997). COMPARATIVE STUDY OF TARGET ANTIGENS FOR PRIMATE XENOREACTIVE NATURAL ANTIBODIES IN PIG AND RAT ENDOTHELIAL CELLS1. Transplantation. 64(8). 1166–1174. 21 indexed citations
14.
Mirenda, Vincenzo, Maryse Fiche, Karen Thibaudeau, et al.. (1997). Pig pancreatic islet xenografts in a B-cell-deficient mouse model. Transplantation Proceedings. 29(1-2). 762–763. 5 indexed citations
15.
Azimzadeh, Agnes M., Ignacio Anegón, Karen Thibaudeau, et al.. (1997). Removal of anti-Galα(1,3)Gal antibodies diminishes the cytotoxic effect of primate xenoreactive antibodies on rat endothelial cells. Transplantation Proceedings. 29(5). 2337–2337. 2 indexed citations
16.
Thibaudeau, Karen, L Borche, Soulillou Jp, & Dominique Blanchard. (1996). Characterization of porcine platelet glycoproteins recognized by human natural "anti-gal" antibodies. Blood. 87(11). 4636–4642. 15 indexed citations
17.
Wolf, Philippe, Agustin P. Dalmasso, Michel Fabre, et al.. (1996). ASSESSMENT OF HYPERACUTE REJECTION IN A RAT-TO-PRIMATE CARDIAC XENOGRAFT MODEL1. Transplantation. 61(9). 1305–1313. 19 indexed citations
18.
Thibaudeau, Karen, et al.. (1994). HUMAN NATURAL ANTIBODIES TO PORCINE PLATELETS. Transplantation. 57(7). 1110–1114. 11 indexed citations
19.
Borche, L, Karen Thibaudeau, Jean‐Marc Navenot, Jean‐Paul Soulillou, & Dominique Blanchard. (1994). Cytolytic effect of human anti‐Gal IgM and complement on porcine endothelial cells: A kinetic analysis. Xenotransplantation. 1(2). 125–131. 14 indexed citations
20.
Thibaudeau, Karen, et al.. (1994). HUMAN NATURAL ANTIBODIES TO PORCINE PLATELETS. Transplantation. 57(7). 1110–1114. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M Hoffman Breakdown of academic impact, for papers by C Vogt Breakdown of academic impact, for papers by Hannes Kalscheuer Breakdown of academic impact, for papers by Hans-Peter Harthus Breakdown of academic impact, for papers by Sarah E. Ackerman Breakdown of academic impact, for papers by Weiyi Gao Breakdown of academic impact, for papers by Thomas Egebjerg Breakdown of academic impact, for papers by Charles J. Kroger Breakdown of academic impact, for papers by Jean Brown Breakdown of academic impact, for papers by Dag Malm
Rankless by CCL
2026